Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.

Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, Rubino M, Veglia F, Fiorentini C, Cipolla CM.

J Am Coll Cardiol. 2010 Jan 19;55(3):213-20. doi: 10.1016/j.jacc.2009.03.095.

2.

Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.

Sliwa K, Norton GR, Kone N, Candy G, Kachope J, Woodiwiss AJ, Libhaber C, Sareli P, Essop R.

J Am Coll Cardiol. 2004 Nov 2;44(9):1825-30.

3.

Protective effects of carvedilol against anthracycline-induced cardiomyopathy.

Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Inanc T, Oguzhan A, Eryol NK, Topsakal R, Ergin A.

J Am Coll Cardiol. 2006 Dec 5;48(11):2258-62. Epub 2006 Nov 9.

4.

Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment.

Azeka E, Franchini Ramires JA, Valler C, Alcides Bocchi E.

J Am Coll Cardiol. 2002 Dec 4;40(11):2034-8.

5.

Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practice.

Massie BM, Nelson JJ, Lukas MA, Greenberg B, Fowler MB, Gilbert EM, Abraham WT, Lottes SR, Franciosa JA; COHERE Participant Physicians.

Am J Cardiol. 2007 May 1;99(9):1263-8. Epub 2007 Mar 13.

PMID:
17478155
6.
7.
8.

Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).

Komajda M, Lutiger B, Madeira H, Thygesen K, Bobbio M, Hildebrandt P, Jaarsma W, Riegger G, Rydén L, Scherhag A, Soler-Soler J, Remme WJ; CARMEN investigators and co-ordinators.

Eur J Heart Fail. 2004 Jun;6(4):467-75.

9.

Effects of carvedilol on left ventricular function and oxidative stress in infants and children with idiopathic dilated cardiomyopathy: a 12-month, two-center, open-label study.

Bajcetic M, Kokic Nikolic A, Djukic M, Kosutic J, Mitrovic J, Mijalkovic D, Jovanovic I, Simeunovic S, Spasic MB, Samardzic R.

Clin Ther. 2008 Apr;30(4):702-14.

PMID:
18498919
10.

Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol.

Capomolla S, Febo O, Gnemmi M, Riccardi G, Opasich C, Caporotondi A, Mortara A, Pinna GD, Cobelli F.

Am Heart J. 2000 Apr;139(4):596-608.

PMID:
10740140
11.

Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?

Yoon GJ, Telli ML, Kao DP, Matsuda KY, Carlson RW, Witteles RM.

J Am Coll Cardiol. 2010 Nov 9;56(20):1644-50. doi: 10.1016/j.jacc.2010.07.023.

12.
13.

A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy.

Botoni FA, Poole-Wilson PA, Ribeiro AL, Okonko DO, Oliveira BM, Pinto AS, Teixeira MM, Teixeira AL Jr, Reis AM, Dantas JB, Ferreira CS, Tavares WC Jr, Rocha MO.

Am Heart J. 2007 Apr;153(4):544.e1-8.

PMID:
17383291
14.

Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure.

Tallaj JA, Franco V, Rayburn BK, Pinderski L, Benza RL, Pamboukian S, Foley B, Bourge RC.

J Heart Lung Transplant. 2005 Dec;24(12):2196-201.

PMID:
16364871
15.

Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey.

Cohen Solal A, Leurs I, Assyag P, Beauvais F, Clerson P, Contre C, Thebaut JF, Genoun M; French National College of Cardiologists.

Arch Cardiovasc Dis. 2012 Jun-Jul;105(6-7):355-65. doi: 10.1016/j.acvd.2012.04.003. Epub 2012 Jun 28.

16.

Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis.

Schleman KA, Lindenfeld JA, Lowes BD, Bristow MR, Ferguson D, Wolfel EE, Abraham WT, Zisman LS.

J Card Fail. 2001 Mar;7(1):4-12.

PMID:
11264544
17.

Combination therapy with carvedilol and amiodarone in patients with severe heart failure.

Nägele H, Bohlmann M, Eck U, Petersen B, Rödiger W.

Eur J Heart Fail. 2000 Mar;2(1):71-9.

18.

Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure.

Maack C, Elter T, Nickenig G, LaRosee K, Crivaro M, Stäblein A, Wuttke H, Böhm M.

J Am Coll Cardiol. 2001 Oct;38(4):939-46.

19.

Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol.

Khattar RS, Senior R, Soman P, van der Does R, Lahiri A.

Am Heart J. 2001 Oct;142(4):704-13.

PMID:
11579363
20.

Effects of carvedilol on ventriculo-arterial coupling in patients with heart failure.

Razzolini R, Tarantini G, Boffa GM, Orlando S, Iliceto S.

Ital Heart J. 2004 Jul;5(7):517-22.

PMID:
15487269

Supplemental Content

Support Center